Department of Surgery

Medicine and Dentistry

1. Abdominal Cancer 100%
2. Liver Transplantation 91%
3. Neoplasm 81%
4. Recurrent Disease 80%
5. Breast Cancer 76%
6. Living Donor 63%
7. Hepatocellular Carcinoma 56%
8. Overall Survival 55%
9. Hepatectomy 55%
10. Lymph Node Metastasis 51%
11. Prognostic Factor 44%
12. Gastrectomy 41%
13. Malignant Neoplasm 39%
14. Survival Rate 38%
15. Tumor 34%
16. Hazard Ratio 33%
17. Disease Free Survival 33%
18. Colorectal Carcinoma 31%
19. Rectum Cancer 30%
20. Pancreaticoduodenectomy 29%
21. Lymph Node 26%
22. Diseases 26%
23. Chemoradiotherapy 26%
24. Papillary Thyroid Cancer 25%
25. Kidney Transplantation 24%
26. Pancreas Cancer 23%
27. Multivariate Analysis 23%
28. Retroperitoneal Lymph Node Dissection 22%
29. Chemotherapy 22%
30. Surgeon 21%
31. Cancer 21%
32. Cohort Analysis 21%
33. Magnetic Resonance Imaging 20%
34. Kidney Graft 20%
35. Retrospective Study 20%
36. Liver Graft 19%
37. Recurrence Free Survival 18%
38. Pancreas Adenocarcinoma 18%
39. Colon Carcinoma 18%
40. Hepatic Portal Vein 17%
41. Cholangiocarcinoma 17%
42. Odds Ratio 17%
43. Postoperative Complication 17%
44. Quality of Life 17%
45. Propensity Score Matching 17%
46. Surgery 17%
47. Neoadjuvant Chemotherapy 16%
48. Thyroidectomy 16%
49. Long-Term Outcome 16%
50. Deceased Donors 15%
51. Radiation Therapy 14%
52. Retrospective Cohort Study 14%
53. Adenocarcinoma 14%
54. Prediction Model 14%
55. Graft Survival 13%
56. Biopsy Technique 13%
57. Computer Assisted Tomography 13%
58. Bile Duct 13%
59. Cancer Surgery 13%
60. Median Follow Up 13%
61. Randomized Controlled Trial 13%
62. Laparoscopic Surgery 13%
63. Pancreas Fistula 12%
64. Stomach 12%
65. Tumor Recurrence 12%
66. Morbidity 12%
67. Pancreatectomy 11%
68. Pediatrics 11%
69. Carcinoma 11%
70. Adjuvant Chemotherapy 11%
71. Primary Tumor 11%
72. Adjuvant Therapy 11%
73. Intraductal Papillary Mucinous Tumor 11%
74. Surgical Margin 11%
75. Proportional Hazards Model 10%
76. Gamma Urogastrone 10%
77. Mastectomy 10%
78. Surgical Anastomosis 10%
79. Cancer Staging 10%
80. Bleeding 10%
81. Distant Metastasis 10%
82. Echography 10%
83. Metastatic Carcinoma 10%
84. Epidermal Growth Factor Receptor 2 10%
85. Radiofrequency Ablation 9%
86. Body Mass Index 9%
87. Hormone Receptor 9%
88. Endoscopic Surgery 9%
89. Artificial Intelligence 9%
90. Treatment Outcome 9%
91. Graft Failure 9%
92. Bile Duct Cancer 9%
93. Predictive Factor 9%
94. Triple Negative Breast Cancer 9%
95. Clinical Significance 9%
96. Positron Emission Tomography-Computed Tomography 9%
97. Genetics 9%
98. Incision 9%
99. Area under the Curve 8%
100. Neoadjuvant Therapy 8%